摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,10S,11R)-10,16-dihydroxy-21-methyl-6-(pyrrolidine-1-carbonyl)-4,21-diazapentacyclo[9.7.3.01,10.03,8.013,18]henicosa-3(8),6,13(18),14,16-pentaen-5-one

中文名称
——
中文别名
——
英文名称
(1R,10S,11R)-10,16-dihydroxy-21-methyl-6-(pyrrolidine-1-carbonyl)-4,21-diazapentacyclo[9.7.3.01,10.03,8.013,18]henicosa-3(8),6,13(18),14,16-pentaen-5-one
英文别名
——
(1R,10S,11R)-10,16-dihydroxy-21-methyl-6-(pyrrolidine-1-carbonyl)-4,21-diazapentacyclo[9.7.3.01,10.03,8.013,18]henicosa-3(8),6,13(18),14,16-pentaen-5-one化学式
CAS
——
化学式
C25H29N3O4
mdl
——
分子量
435.5
InChiKey
NCOGSZMTKJPNLS-NQHRYMMQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    32
  • 可旋转键数:
    1
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    93.1
  • 氢给体数:
    3
  • 氢受体数:
    5

文献信息

  • [EN] PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS<br/>[FR] ANALOGUES DE PYRIDONEMORPHINANE ET ACTIVITÉ BIOLOGIQUE SUR DES RÉCEPTEURS DES OPIOÏDES
    申请人:PURDUE PHARMA LP
    公开号:WO2014091295A1
    公开(公告)日:2014-06-19
    The application is directed to compounds of Formula (I-A) and pharmaceutically acceptable salts and solvates thereof, wherein Formula (II), R1a, R2a, R3a, R4 and Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    该应用程序涉及公式(I-A)的化合物及其药用可接受的盐和溶剂化合物,其中公式(II),R1a,R2a,R3a,R4和Za的定义如规范所述。该发明还涉及使用公式I-A的化合物来治疗对调节一个或多个阿片受体敏感的疾病,或作为合成中间体。本发明的某些化合物特别适用于治疗疼痛。
  • PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS
    申请人:Purdue Pharma LP
    公开号:EP2931724B1
    公开(公告)日:2017-01-25
  • Pyridonemorphinan Analogs and Biological Activity on Opioid Receptors
    申请人:Purdue Pharma L.P.
    公开号:US20140187549A1
    公开(公告)日:2014-07-03
    The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein , R 1a , R 3a , R 4 , Y and Z a are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
  • HETEROCYCLIC MORPHINAN DERIVATIVES AND USE THEREOF
    申请人:Purdue Pharma L.P.
    公开号:US20180111934A1
    公开(公告)日:2018-04-26
    The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , and Z are defined as set forth in the specification. In certain embodiments, the invention is also directed to compounds of Formula II-VII and the pharmaceutically acceptable salts and solvates thereof. The invention is also directed to use of compounds of Formula I to VII, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the invention are especially useful for treating pain.
  • US8980906B2
    申请人:——
    公开号:US8980906B2
    公开(公告)日:2015-03-17
查看更多